• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

125
16
12
10
9

COUNTRY

4
4
3
3
2

PRICE

91
121
268
456

PUBLISHED

46
56
116
456

PRODUCT TYPE

449
6
1

Immune Disorders

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014’, provides an overview of the Plaque...

February 2014
FROM

Rheumatoid Arthritis - Pipeline Review, H1 2014

Rheumatoid Arthritis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Rheumatoid Arthritis - Pipeline Review, H1 2014’, provides an overview of the Rheumatoid Arthritis’s therapeutic pipeline. This...

February 2014
FROM

Osteoarthritis - Pipeline Review, H1 2014

Osteoarthritis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Osteoarthritis - Pipeline Review, H1 2014’, provides an overview of the Osteoarthritis’s therapeutic pipeline. This report...

February 2014
FROM

Systemic Lupus Erythematosus - Pipeline Review, H1 2014

Systemic Lupus Erythematosus - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Systemic Lupus Erythematosus - Pipeline Review, H1 2014’, provides an overview of the Systemic Lupus Erythematosus’s...

February 2014
FROM

Lung Transplantation - Pipeline Review, H1 2014

Lung Transplantation - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This...

January 2014
FROM

Humira (Crohn's Disease) - Forecast and Market Analysis to 2022

Humira (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

Entyvio (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - Canada Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These...

January 2014
FROM

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

Cimzia (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

Vercirnon (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds...

January 2014
FROM

PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - Japan Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These...

January 2014
FROM

Lupus Nephritis Global Clinical Trials Review, H1, 2014

Lupus Nephritis Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial...

January 2014
FROM

PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - China Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These...

January 2014
FROM

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

Prochymal (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds...

January 2014
FROM

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

Stelara (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

PharmaPoint: Crohn's Disease - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - US Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds...

January 2014
FROM

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

Remicade (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

Tysabri (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - Global Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such...

January 2014
FROM

PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon These compounds will challenge the current biologics in an attempt to dislodge the stronghold...

January 2014
FROM
Loading Indicator

Our Clients

Our clients' logos